MozambiqueTuberculosis profile
Population  2014 27 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 18 (12–26) 67 (44–96)
Mortality (HIV+TB only) 37 (29–45) 134 (106–165)
Prevalence  (includes HIV+TB) 150 (80–240) 554 (295–893)
Incidence  (includes HIV+TB) 150 (120–180) 551 (435–680)
Incidence (HIV+TB only) 85 (65–110) 311 (237–395)
         
Case detection, all forms (%) 39 (31–49)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 3.5 (2.2–4.8) 11 (0–25)
MDR-TB cases among notified pulmonary
TB cases
1 700 (1 100–2 300) 460 (0–1 000)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 24 430   1 542
Pulmonary, clinically diagnosed 23 455   2 070
Extrapulmonary 6 276    
       
Total new and relapse 57 773    
Previously treated, excluding relapses 497    
Total cases notified 58 270    
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 886 (4%) 906 (22%) 3 716
Laboratory-confirmed RR-/MDR-TB cases     544
Patients started on MDR-TB treatment ***     482
TB/HIV 2014 Number (%)
TB patients with known HIV status 55 943 (96)
HIV-positive TB patients 29 337 (52)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 27 504 (94)
HIV-positive TB patients on antiretroviral therapy (ART) 23 801 (81)
HIV-positive people screened for TB 563 377  
HIV-positive people provided with IPT 94 252  
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (88) 23 072
Previously treated cases registered in 2013    
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (28) 214
XDR-TB cases started on second-line treatment in 2012   4
Laboratories 2014  
Smear (per 100 000 population) 1.2
Culture (per 5 million population) 0.6
Drug susceptibility testing (per 5 million population) 0.4
Sites performing Xpert MTB/RIF 24
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 29
% Funded domestically 6%
% Funded internationally 66%
% Unfunded 28%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-02-12 Data: www.who.int/tb/data